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Abstract 
 
 
 
 
 
 
 
Natural killer cells are the main agents of innate immunity. Since 1970, various 
studies have repeatedly confirmed their involvement in decreasing local tumor 
growth and also decreasing the risk of metastasis, due to their cytotoxic effects and 
also through the release of immunostimulatory cytokines such as IFN-gamma. In the 
1990s, several studies demonstrated the existence of certain inhibiting and 
stimulating receptors of these cells, leading to the concept of “induced self”, thus 
explaining why tumors with MHC-1 are destroyed and autologous cells without it 
are saved out. Recognition and destruction of tumor cells by the NK cells are the 
result of complex interactions between inhibiting and activating factors. This paper, 
based on extensive research of currently available studies, summarizes the 
mechanisms employed by the NK cells to destroy the cancer cells, thus highlighting 
their role in the risk of tumor recurrence as well as their use and handling in certain 
types of immunotherapy. 
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Introduction 
In 1975, interest was raised by the identification of 
certain cells with lymphocyte morphology, present in 
both humans and mice, cells with the ability to destroy 
modified cells without being previously activated (1). 
The difference between B and T lymphocytes is 
represented by the existence of a primary entity that does 
not require activation (2).  
Karre and colleagues introduced the “missing self” 
hypothesis that basically stipulates that these cells have 
the ability to detect and destroy cells with MHC-1 
deficiency (major histocompatibility complex) (3). In the 
1990s, several studies demonstrated the existence of 
certain inhibiting and stimulating receptors of the NK 
cells, leading to the concept of “induced self”, thus 
explaining why tumors with MHC-1 are destroyed and 
autologous cells without expression of MHC-1 are saved 
out (4).      
Consequently, these cells can identify and destroy a 
wide range of abnormal cells (tumor cells, virally 
infected cells, cells coupled with antibodies, cells under 
a certain degree of stress), preserving healthy “self” cells 
(5). NK cells represent 5-20% of the mononuclear 
peripheral blood cells, usually defined as CD16+, CD 
56+, CD3- and are found in the liver, peritoneal cavity, 
placenta and the uterine mucosa (6).  
Depending on the density of CD16 and CD56 
present on the surface, NK cells can be divided into two 
subpopulations: CD56 dim (moderate presence of CD56, 
predominantly displaying CD16 – and with high 
cytotoxic potential) and CD56 bright (CD16 presence 
greatly reduced, reduced cytotoxicity but with high 
cytokine production after activation) (7). Recently, a 
new NK cell marker – NKp46- has been discovered in 
humans and mice (8, 9). 
 
 
 
Discussion 
 The role of NK cells in cancer 
Growth and tumor invasion are the result of 
interactions between the tumor and the surrounding 
tissues, by initiating angiogenesis and the involvement 
of the immune system (innate and acquired). 
Clinicopathological signification of these processes is 
given by the infiltration of the tumor with lymphocytes. 
Lymphocytes T CD8+ and NK cells are representative 
agents of the anti-tumoral immunity (10).  
Some studies have shown a link between the number 
of lymphocytes and survival in certain types of cancer, 
as the lower the number of NK liver cells the more 
advanced the neoplasm. These results suggest that the 
metastasis is due to ineffective antitumor liver 
mechanisms because of a low number of NK cells (11, 
12). Studies were extended in order to explain the 
decline in the number of the NK cells in advanced 
cancer stages, demonstrating that the tumor allegedly 
inhibits the NK activating receptors and stimulates the 
 
 
Figure 1. The High and Low-Cytokine Production 
(schematic representation) (9). 
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inhibitory receptors, thus conducing to metastatic 
expansion (13).  
These results have defined the concept of the tumor 
cell associated with the NK cell phenotype – NK 
humoral infiltrates (14-16). In certain cancers, not only 
NK cells present in the tumor may have different 
phenotypes or display a decrease in cytotoxicity but also 
the NK cells in the peripheral blood may show the same 
changes (studies done on patients with metastatic 
malignant melanoma have ascertained the reduction of 
NK cell activity and a reduction of IFN gamma 
production as well as an increase in CD16 in the 
detriment of the CD56 bright). Although the molecular 
mechanisms responsible for reducing receptor activity in 
peripheral blood are not yet known, the hypothesis is 
that the increase in the soluble serum values of tumor 
receptors would inhibit the cell receptors, contributing to 
a diminished NK cell activity. It is certain that the NK 
cells have a tumor fighting potential but, taken in 
consideration the results mentioned above, work must 
continue towards fully understanding and activating this 
potential (17). 
 Mechanisms of action for natural killer cells 
NK cells recognize target cells via receptors on the 
cell surface, which can be inhibited or stimulated by 
various conditions. For NK cells to be active, the 
receptors must be stimulated. Until now we know 3 
types of NK cell action:  
1. Throughout perforin-granzime system. Releasing 
of these cytotoxic beads is the fastest and the most 
effective mechanism for cell lysis. Trials made on 
perforin-deficient mice have shown a reduced ability of 
tumor lysis, suggesting that perforins are indispensable 
for NK cell cytotoxicity. Several studies have shown the 
importance of perforins in tracking the cancer relapse 
risk. The role of granzimes is not understood yet (18); 
2. The induction of apoptosis is done by the TNF 
ligand family. This mechanism is slower (several hours) 
and less efficient. It needs the presence of TNF ligands 
on the cellular surface, ligands that will latch onto the 
Fas receptors on the surface of the target cells (19); 
3. Through the activity of the IFN-gamma, the 
activated NK cells secrete numerous cytokines (IFN-g, 
TNF-alpha, IL-10, IL-13 etc.). Among IFN effects, the 
following must be highlighted: inhibits cell proliferation 
in vitro and indirectly slows tumor growth in vivo by 
stimulating anti-angiogenic factors; increases the 
sensitivity of tumor cells to the action of perforins and 
apoptosis; elimination of sarcoma and metastasis 
induced by methylcholanthrene (carcinogenic chemical 
agent); stimulates the dendritic cells, by which it 
indirectly contributes to tumor control, by means of T-
lymphocytes (20). 
 
Figure 2. The schematic view of the mechanism of 
action and innate killing of a NK cell (with permission 
from http://nantkwest.com/platform/). 
 
 The role of NK cells in limiting the tumor growth 
and metastasis 
The current advances in this field have established 
some facts. Among them: 
 It has been shown in mice that the tumor 
cytotoxicity depends on the presence of cell surface 
ligands. There is little available information about the 
mechanisms of NK cell migration in tumors, while it is 
established that selectins play a role in this process (21). 
 Mice with a low NK cell count have a higher 
predisposition to chemical induced neoplasms, hence a 
role of NK cells in tracking risk of developing 
malignancies can be considered (22).  
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 Experiments on animals have shown the ability of 
NK cells to inhibit the development of lung metastasis 
following treatment with IFN.   
 An 11-year study on humans has shown an increased 
risk of developing malignancy in patients with low 
activity of NK cells (for example, patients with 
hereditary colorectal adenocarcinoma and metastatic 
melanoma have an altered mechanism of perforins (23).  
 Following administration of tumor cells in mice, NK 
cells released IFN, which stimulated dendritic cells, 
promoting a strong anti-tumor response of lymphocytes 
T CD8+ ( 24).  
 The involvement of NK cells in the anti-tumor 
management  
Although we know the NK cells advantage over the 
T lymphocyte cells in the anti-tumor fight, their 
therapeutic potential yet remains unexplored. Research 
on the scientific mechanisms of enhancing or inhibiting 
NK cells as well as methods to make tumor cells 
receptive to the cytotoxic activity of the NK cells led to 
the development of numerous genetic and 
pharmacological methods to increase NK cell activity:  
 Cytokine administration 
The potential of the IL-2 to enhance NK cytotoxicity 
was observed in vitro. This finding led to conducting 
clinical trials on patients with metastatic melanoma and 
renal carcinoma. Trials in primates have shown 
increased systemic toxicity of IL-2, so that Berger used 
IL-15 with IL-2 like properties, considering appropriate 
the intermittent administration of IL-15 (25).  
 Monoclonal antibody therapy 
Administration of monoclonal antibodies to target 
the tumor may induce rapid degranulation of NK cells 
and cell lysis. The efficiency of the monoclonal 
antibodies anti-CD20 (Rituximab), anti-Her2 
(Transtuzumab™), receptors for epidermal growth factor 
(Cetuximab™) is due partially to the cytotoxicity of NK 
cells antibody-addicted (26-28). 
 Blocking the inhibitory receptors 
Blocking the inhibitors receptors Ly49 increases 
tumor activity both in vivo and in vitro. Current 
experiments test antibodies which block KIR (post-
transplant of hematopoietic stem cells) (29).  
 Vaccinating the tumor with dendritic cells is 
currently in the (early) experimental stage (30).  
 Ongoing clinical studies on NK cells 
 Study of the Combined Therapy for Pancreatic 
Cancer (Fuda Cancer Hospital, Guangzhou). This study 
focuses on finding the differences in behavior of 
advanced pancreatic cancer patients that received both 
irreversible electroporation (IRE) and immunotherapy of 
nature killer (NK) cells versus patients that received only 
immunotherapy of nature killer (NK) cells without 
irreversible electroporation (IRE). It is in progress since 
2016; 
 Intraperitoneal Natural Killer Cells and 
INCB024360 for Recurrent Ovarian, Fallopian Tube, 
and Primary Peritoneal Cancer (Masonic Cancer Center, 
University of Minnesota, USA). This is a single center 
phase I trial designed to determine the maximum 
tolerated dose (MTD) of the oral IDO inhibitor 
INCB024360 when administered as part of a larger 
regimen of intraperitoneal (IP) delivery of haplo 
identical donor NK cells and IL-2after a non-
myeloablative cyclophosphamide/ fludarabine (Cy/Flu) 
preparative regimen for the treatment of recurrent 
ovarian, fallopian tube, and primary peritoneal cancer; 
 Natural Killer Cells Plus IL-2 Following 
Chemotherapy to Treat Advanced Melanoma or Kidney 
Cancer (National Cancer Institute, USA)- This study 
determines the ability of the administration of 
autologous natural killer (NK) cells plus aldesleukin (IL-
2) following a non-myeloablative lymph depleting 
preparative regimen to mediate tumor regression in 
patients with metastatic melanoma or kidney cancer, to 
determine the rate of repopulation of the natural killer 
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cells in treated patients and to find the overall toxicity of 
this treatment regimen; 
 NK Cell Infusions with Trastuzumab™ for 
Patientswith HER2+ Breast and Gastric Cancer 
(National University Hospital, Singapore). This study 
focuses on the ability of Transtuzumab, a monoclonal 
antibody against HER-2 positive breast or gastric cancer, 
to deliver cytotoxic effects. It is used in combination 
with immunotherapy in treating HER2- positive tumor 
cells. This study will determine the response of the 
expanded activated autologous NK cells administered 
after Trastuzumab in patients with HER2-positive breast 
or gastric cancer. 
 Natural Killer Cells and Bortezomib™ to Treat 
Cancer (National Institutes of Health Clinical Center, 
USA). This ongoing study is centered on the idea that 
pre-administration of Bortezomib™ makes NK cells 
more sensitive to TNF-related apoptosis-inducing ligand 
(TRAIL), as in vitro studies have already confirmed. 
This study will determine if there are the same effects in 
vivo as well. 
 NK White Blood Cells and Interleukin in Children 
and Young Adults with Advanced Solid Tumors 
(National Cancer Institute, USA). This study will 
determine the safety and efficacy of administration of 
activated NK cells in solid tumors at children and young 
adults. 
 
Conclusions 
 
NK cells could be real weapons in the anti-tumor 
fight and could be employed to induce an optimal 
immune response against cancer. A better understanding 
of the molecular mechanisms of action of the NK cells 
provides the way for the development of new strategies 
to manipulate these cells in the fight against cancer. 
 
Acronyms and abbreviations: 
NK: Natural Killer; MHC-1: major histo-
compatibility complex;  
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